+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of stent placement for vena cava syndrome: phase II trial and phase III randomized controlled trial



Evaluation of stent placement for vena cava syndrome: phase II trial and phase III randomized controlled trial



Supportive Care in Cancer 27(3): 1081-1088



Vena cava syndrome (VCS) from stenosis of the superior vena cava or inferior vena cava caused by compression from a malignant tumor is one of the typical clinical conditions in patients with advanced stage malignant disease. VCS is difficult to manage and painful, reducing patients' quality of life. Although several reports have investigated stent placement for VCS, this treatment has never been established as the standard because of the lack of evidence of the safety and efficacy. We conducted a phase II trial and a phase III randomized controlled trial to clarify the role of stent placement in managing patients with VCS. In the phase II trial, 28 eligible patients were treated with stent placement. The efficacy of stent placement for VCS was evaluated based on the reduction of patients' symptom scores during 14 days following treatment. Technical success, technical feasibility, overall survival, recurrence of symptoms, and adverse events were evaluated. In the phase III trial, 32 patients were enrolled and randomly assigned to the test (n = 16) and control groups (n = 16). The area under the symptom score curve was compared between the groups. The EQ-5D, SF-8, and adverse events were evaluated until discontinuation of the protocol treatment or 28 days after enrollment. In the phase II trial, the median patients' symptom scores significantly decreased from 10.50 before the procedure to 3.00 after the procedure. Technical success and technical feasibility rates were 96.4% and 100%, respectively. The incidence of treatment-related grade 3 or higher adverse events was 14.3%. In the phase III trial, significant superiority of stent placement was observed in the test, compared to that in the control, group. There was no significant difference in most other evaluations between the groups. Stent placement significantly improved the symptoms of VCS; thus, it might be accepted as the standard treatment to manage the symptoms of VCS. JIVROSG-0402, JIVROSG-0807.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 063303441

Download citation: RISBibTeXText

PMID: 30112721

DOI: 10.1007/s00520-018-4397-5


Related references

Neoadjuvant chemotherapy vs radiotherapy alone for superior vena cava syndrome due to non-small cell lung cancer Preliminary results of randomized phase II trial. European Journal of Cancer 35(Suppl. 4): S260, 1999

Bridging stent placement through the superior vena cava to the inferior vena cava in a patient with malignant superior vena cava syndrome and an iodinated contrast material allergy. Japanese Journal of Radiology 32(8): 496-499, 2014

Higher quality of life after metal stent placement compared with plastic stent placement for malignant extrahepatic bile duct obstruction: a randomized controlled trial. European Journal of Gastroenterology and Hepatology 29(2): 231-237, 2017

Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials 12: 255, 2011

A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial). Circulation. Cardiovascular Interventions 2(2): 113-123, 2009

Health-related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. The Dutch Iliac Stent Trial Study Group. Circulation 99(24): 3155-3160, 1999

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials 17(1): 293, 2016

A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials 19(1): 293, 2018

Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatology Research 48(6): 411-423, 2018

Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. Trials 17(1): 459, 2016

Intraureteral lidocaine for ureteral stent symptoms post-ureteroscopy: A randomized, phase 2, placebo-controlled trial. Canadian Urological Association Journal 11(10): 326-330, 2017

Time for a relevant randomized controlled trial of vena cava filters. Journal of the American Osteopathic Association 113(1): 11-12, 2013

Superior vena cava rupture during balloon angioplasty and stent placement to relieve superior vena cava syndrome: a case report. Heart Surgery Forum 10(1): E78-E80, 2007

Randomized, Placebo-Controlled Trial of Dobutamine for Low Superior Vena Cava Flow in Infants. Journal of Pediatrics 167(3): 572-8.E1-2, 2015

A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. American Journal of Kidney Diseases 60(2): 272-279, 2012